InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
Aditxt (NASDAQ:ADTX) provided an update on its subsidiary, Adimune, Inc., and the progress of ADI-100, an investigational gene therapy targeting autoimmune diseases such as psoriasis, Type 1 diabetes, and Stiff Person